By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > News > USANA Earnings Preview: From China’s Challenge To India’s Promise (NYSE:USNA)
News

USANA Earnings Preview: From China’s Challenge To India’s Promise (NYSE:USNA)

News Room
Last updated: 2023/07/21 at 4:52 AM
By News Room
Share
9 Min Read
SHARE

Contents
IntroductionRevisiting USANA’s ChallengesKey Things To WatchConclusion

Introduction

Navigating through the turbulent waters of COVID-19 and China’s stringent lockdown measures, numerous companies including USANA Health Sciences (NYSE:USNA), faced a challenging period. In a previous piece, I delved into how USANA is strategically positioning itself to reap the benefits of China’s recovery. Fast forward to now, the company is on the brink of releasing its quarterly results. USANA is scheduled to report after the market closes on Tuesday, July 25, followed by a conference call on July 26. Unquestionably, the impact of China on the earnings will be a focal point in the release, but there are a couple of other significant elements to keep an eye on. Despite the possibility of reporting a decline in revenues and earnings, there’s still a promising horizon to anticipate.

Revisiting USANA’s Challenges

USANA Health Sciences, a manufacturer and distributor of nutritional, dietary, and personal care products, has a wide reach across numerous markets, though nutritional products account for over 85% of its sales. The company has established its presence in 24 global markets, with China being its largest, accounting for half of its total revenue. Lately, however, USANA has been wrestling with decreasing revenue, profits, and active customer counts, primarily owing to China’s economic deceleration as well as inflation, pandemic-induced constraints, and the global economic slowdown.

Based on the company’s predictions, it anticipates EPS ranging from $2.40 to $3.30 per share from revenues of between $875 million and $950 million for 2023. The midpoint of this forecast signifies a revenue reduction of 8.66% and a plunge in earnings by 20.6%. In the first quarter of 2023, USANA reported a profit of $0.95 per share, showing a year-over-year decrease of 17%, and a revenue of $248 million, representing a 9% year-over-year decline. The total number of active customers reached 491,000, marking an 11% dip compared to the same quarter of the previous year.

However, it hasn’t been all bleak. Encouragingly, China’s economic resurgence post its extensive lockdown and travel restriction periods might favorably impact USANA’s performance. The company has also accelerated its marketing initiatives in China to take advantage of this economic recovery. This renewed focus is something I believe will be highlighted in the upcoming earnings report, and I will be keenly looking for signs of stabilization, potentially indicating growth in the years to come. More precisely, I will be honing in on three particular areas in the company’s earnings report.

Key Things To Watch

It’s crucial to keep in mind that USANA is recovering from a downturn, and I believe a swift turnaround is improbable. Persistent inflation and the broader economic slump are likely to continue casting shadows over the company’s performance. As the Chinese market recuperates and USANA’s sales team resumes fieldwork, there would be a period of settling and stabilization. Thus, I am not forecasting an immediate and vigorous recovery, a sentiment echoed in the earnings projections by analysts collated by Seeking Alpha. The consensus anticipates USANA to post a profit of $0.70 per share, a 30% drop from Q2-2022, and revenues of $231.14 million, a decrease of 12.45% from the previous year.

USNA Earnings Forecast

Seeking Alpha

Firstly, the impact of price increases on USANA’s earnings will be a significant indicator to monitor. The company hiked prices for its products across most markets at the end of the first quarter. This annual tradition typically prompts a surge in buying activity as active customers stock up at lower prices before the increase comes into effect, which we observed in the first quarter. However, I think this scenario demands heightened attention this time for two reasons.

The positive bump from the surge in customer purchases reached an unusually high level at $13 million in Q1-2023. This trend may retract in the second quarter, negatively affecting the company’s performance. Additionally, the actual increase applied by the company was steeper than its usual adjustments. USANA typically adjusts prices by 1% to 2%, but this year it enacted a weighted average increase of 4%. This above-normal increment was attributed to the strain from high costs of raw materials and supply chain disruptions. I suspect this above-average price hike could impact the company’s sales across various markets, particularly in a climate where consumers are already grappling with inflation. Such an environment might present challenges for the company in struggling markets like the Americas and Europe, which reported a sales decline of 10.7% in the first quarter.

Secondly, investors should anticipate further insights into USANA’s global expansion ambitions, which could influence the company’s long-term trajectory. It’s worth recollecting that the company previously revealed its preparations to penetrate a new market this year, which I thought could start contributing to growth from 2024 onwards. At the time of my previous article, the company hadn’t disclosed the identity of this new market. However, it later revealed its strategic intention to expand in India.

International expansion forms one of the cornerstones of USANA’s strategy, but it has been half a decade since the company last ventured into a new market-a period that includes the upheavals caused by the COVID-19 pandemic. Now, with COVID-19 in the rearview mirror, it seems USANA is returning to its foundational strategies-a positive development indeed. The company plans to officially commence operations in India around September. I am optimistic about this move, and I believe the Indian market could offer substantial opportunities, especially given the country’s projected rapid economic growth outpacing even China. While I don’t anticipate immediate sales impact, I foresee improvements from 2024 as the company scales up operations and builds its sales force. I look forward to more insights about the Indian venture during USANA’s post-earnings conference call.

Thirdly, and perhaps most crucially, signs of recovery in China will be a significant aspect to watch. As noted earlier, the company’s operations in its largest market were severely impacted due to COVID-induced lockdowns and economic conditions. However, the reopening of China has sparked some optimism for the company. In the second quarter, USANA resumed live meetings to rejuvenate its sales force and revive sales. For the first time in about three years, it held a significant event-the China National Sales Meeting in Macau, attended by 10,000 associates. The company has plans for additional minor events throughout the year, which should begin to positively affect its performance in China.

In the first quarter, USANA’s sales and active customer count in China decreased by 7% and 5%, respectively, on a YoY basis. Still, these declines were less severe compared to the company-wide averages. For the second quarter, I anticipate the company to report an improvement in both its sales numbers in China (particularly on a constant currency basis) and active customer count, especially in the wake of the large sales event. There might be signs of stabilization leading to potential growth, especially in the second half of the year.

Conclusion

In summary, it’s probable that USANA will report a further decline in both revenues and earnings, echoing the ongoing challenges the company faces. However, amidst this hardship, glimmers of hope are visible. The influence of the recent price increase, revelations regarding the foray into the Indian market, and early signs of resurgence in China present a cautious optimism for future progress. As the company navigates these turbulent times, these positive indicators could chart the course for recovery and future growth.

Read the full article here

News Room July 21, 2023 July 21, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Strategy suffers billions in losses, Netflix reportedly bids on Warner Bros Discovery

Watch full video on YouTube

Medical Office And AI Data Center Lead Biggest Commercial Real Estate Deals

Watch full video on YouTube

Bitcoin rises, OpenAI CEO Sam Altman declared ‘code red’ as competition heats up

Watch full video on YouTube

Why More Students Are Forgoing Four-Year College

Watch full video on YouTube

Comus Investment 2025 Annual Letter

Dear Partners, We had a good year in 2025, however we were…

- Advertisement -
Ad imageAd image

You Might Also Like

News

Comus Investment 2025 Annual Letter

By News Room
News

Trump names Tony Blair, Jared Kushner and Marc Rowan to Gaza ‘Board of Peace’

By News Room
News

Is the US about to screw SWFs?

By News Room
News

KRE ETF: Stabilization With A CRE Overhang (NYSEARCA:KRE)

By News Room
News

Goldman and Morgan Stanley investment bankers ride dealmaking wave

By News Room
News

AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

By News Room
News

White House sets tariffs to take 25% cut of Nvidia and AMD sales in China

By News Room
News

AI: Short Circuit? | Seeking Alpha

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?